bioRxivSystems BiologyPreprint
Personalized modeling of the human gut microbiome reveals distinct bile acid deconjugation and biotransformation potential in healthy and IBD individuals
Almut HeinkeniD, Dmitry A. RavcheeviD, Federico BaldiniiD, Laurent HeirendtiD, Ronan M. T. FlemingiD, Ines ThieleiD
Abstract
The human gut microbiome performs important functions human health and disease. Intestinal microbes are capable of deconjugation and biotransformation of human primary bile acids to secondary bile acids. Alterations of the bile acid pool as a result of microbial dysbiosis have been linked to multifactorial diseases, such as inflammatory bowel disease (IBD).\n\nConstraint-based modeling is a powerful approach for the mechanistic, systems-level analysis of metabolic interactions in microbial communities. Recently, we constructed a resource of 773 curated genome-scale reconstructions of human gut microbes, AGORA. Here, we performed a comparative genomic analysis of bile acid deconjugation and biotransformation pathways in 693 human gut microbial genomes to expand these AGORA reconstructions accordingly (available at http://vmh.life).\n\nTo elucidate the metabolic potential of individual microbiomes, publicly available metagenomic data from a cohort of healthy Western individuals, as well as two cohorts of IBD patients and healthy controls, were mapped onto the reference set of AGORA genomes. We constructed for each individual a large-scale personalized microbial community model that take strain-level abundances into account. Using flux balance analysis, we found that distinct potential to deconjugate and tranform primary bile acids between the gut microbiomes of healthy individuals. Moreover, the microbiomes of pediatric IBD patients were significantly depleted in their bile acid production potential compared with controls. The contributions of each strain to overall bile acid production potential across individuals were found to be distinct between IBD patients and controls. IBD microbiomes were depleted in contributions of Bacteroidetes strains but enriched in contributions of Proteobacteria. Finally, bottlenecks limiting secondary bile acid production potential were identified in each microbiome model. For ursodeoxycholate, the abundance of strains producing the precursor rather than of strains directly producing this secondary bile acid was synthesis-limiting in certain microbiomes.\n\nIn summary, we integrated for the first-time metagenomics data with large-scale personalized metabolic modeling of microbial communities. We provided mechanistic insight into the link between dysbiosis and metabolic potential in IBD microbiomes. This large-scale modeling approach provides a novel way of analyzing metagenomics data to accelerate our understanding of the metabolic interactions between human host and gut microbiomes in health and diseases states.
- organism: human
- assay: metagenomics
- research focus: gene regulatory network inference
- approach: statistical model
- Citations
- 28
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Clostridia-rich microbiota contributes to increased excretion of bile acids in diarrhea-predominant irritable bowel syndrome
- Systematic interrogation of the distinct metabolic potential in gut microbiomes of inflammatory bowel disease patients with dysbiosis
Almut Heinken, Ines Thiele·bioRxiv·May 17, 2019
- Host-derived bile acids drive dysbiosis by selecting bile-resistant epimerizing bacteria in inflammatory bowel disease
Maximilian Baumgartner, Franziska Schnaufer, … Clarissa Campbell·bioRxiv·Jun 19, 2026
- A metabolic pathway for bile acid dehydroxylation by the gut microbiome
M. Funabashi, T. Grove, … M. A. Fischbach·bioRxiv·Sep 5, 2019
- Metabolic modeling reveals a multi-level deregulation of host-microbiome metabolic networks in IBD
Jan Taubenheim, A. Samer Kadibalban, … Christoph Kaleta·Nature CommunicationsPeer-reviewed·Jun 2, 2025
- A microbial derived bile acid acts as GPBAR1 agonist and RORγt inverse agonist and reverses inflammation in inflammatory bowel disease
M. Biagioli, C. Di Giorgio, … S. Fiorucci·bioRxiv·Apr 8, 2024